Anika Therapeutics, Inc. (ANIK) is a publicly traded company in the Healthcare — Medical - Specialties industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies.
Analysis Summary
Anika Therapeutics, Inc. reported revenue of $112.8M in the most recent fiscal year, growing at a 5-year CAGR of -2.9%.
Trailing-twelve-month margins: gross margin 62.2%, operating margin -4.2%, net margin -3.1%. Free cash flow grew at -17.5% CAGR over 5 years.
At the current price of $21.03, ANIK has negative trailing earnings (P/E not meaningful) and an ROE of -2.70%. Market capitalisation stands at $281M.
Balance sheet quality for ANIK: current ratio of 4.7, net cash position of $31.2M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $21.03 |
| Market Cap | $281M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.02 |
| EV / EBITDA | 97.19 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -2.70% |
| Return on Invested Capital | -3.17% |
| Return on Assets | -2.06% |
| Gross Margin | 62.16% |
| Operating Margin | -4.24% |
| Net Margin | -3.14% |
Financial Health
| Debt / Equity | 0.17 |
| Current Ratio | 4.48 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ANIK | Anika Therapeutics, Inc. | $279M | 2.02 | -2.7% | |
| ALC | Alcon Inc. | $32.2B | 51.85 | 1.52 | |
| 0A0D.L | Alcon Inc. | $27.1B | |||
| STE | STERIS plc | $20.5B | |||
| 0JZ2.L | Masimo Corporation | $9.5B | 9.69 | -21.0% | |
| 0QLQ.L | Ypsomed Holding AG | $4.8B | |||
| 0A05.L | Medacta Group S.A. | $2.3B |
Price Performance
| 1 month | -2.69% |
| 3 months | +45.56% |
| Year-to-date | +118.42% |
| 1 year | +142.38% |
| 3 years | +23.62% |
52-Week Range
| 52-week High | $22.88 |
| 52-week Low | $8.64 |
| Avg Volume (90d) | 88K |
Related companies: ANIX · APYX · ARAY · AVR · LNSR · LUCD · MXCT
Explore sector: Healthcare · Medical - Specialties
More sections of ANIK: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks